NCT06804512 Intermittent Visual Perturbations to Enhance Balance Training
| NCT ID | NCT06804512 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Florida |
| Condition | Balance |
| Study Type | INTERVENTIONAL |
| Enrollment | 540 participants |
| Start Date | 2024-08-20 |
| Primary Completion | 2029-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 540 participants in total. It began in 2024-08-20 with a primary completion date of 2029-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to determine if intermittent visual perturbations can improve balance training. The investigators will quantify differences in body movement, muscle activity, and beam walking performance during and after practice walking on a balance beam that is 1" high. The investigators will ask the participants to come to the laboratory twice (2 sessions). The first session will not last more than 3 hours. The second session will not last more than 1 hour and will be two weeks after the first session. In total, the maximum amount of time the participant would be asked to participate is 4 hours.
Eligibility Criteria
Inclusion Criteria: * Ages 18-30 years, or 65-89 years. * Ability to walk independently for 10 minutes continuously. * Willingness to be randomized to any experimental group and to participate in all aspects of study assessment and intervention Exclusion Criteria: -Major cognitive disorder that interferes with independence, based on affirmative response (always/usually/sometimes) to the following question: "As a result of confusion or memory loss, how often do you need assistance with day-to-day activities such as cooking, cleaning, taking medications, driving, or paying bills? Would you say it is 1) Always; 2) Usually; 3) Sometimes; 4) Rarely; or 5) Never". * Current or recent (within 6 months) lower limb musculoskeletal injury that causes pain during walking or limits walking ability. * History of neurological injury or disability (including spinal cord injury, stroke, Parkinson's disease, or multiple sclerosis). * Difficulty communicating with study personnel. * Current enrollment in any other clinical trial. * Low vision that cannot be corrected by wearing contact lens. Low vision will be operationally defined as visual acuity less than 20/70 on standard eye chart, or difficulty perform complex walking tasks due to visual conditions affecting accurate navigation around and over obstacles (self-reported or observed by examiner). The goggles to be used in the study do not permit eyeglasses while using them. * Illiterate or non-English speaking, due to the likelihood of difficulties following protocol instructions.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06804512 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Balance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06804512 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06804512 currently recruiting?
Yes, NCT06804512 is actively recruiting participants. Contact the research team at dferris@bme.ufl.edu for enrollment information.
Where is the NCT06804512 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT06804512 clinical trial?
NCT06804512 is sponsored by University of Florida. The trial plans to enroll 540 participants.